Condition: Colitis, Ulcerative · Sponsor: Bristol-Myers Squibb
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Local Institution - 0041 | Phoenix, Arizona, United States | Withdrawn |
| University of Arizona | Tucson, Arizona, United States | Withdrawn |
| Local Institution - 0052 | Garden Grove, California, United States | Completed |
| Loma Linda University Health System | Loma Linda, California, United States | Recruiting |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Lucile Packard Children's Hospital | Palo Alto, California, United States | Not Yet Recruiting |
| University of California Davis Health | Sacramento, California, United States | Recruiting |
| Local Institution - 0007 | Hartford, Connecticut, United States | Completed |
| Local Institution - 0064 | Washington D.C., District of Columbia, United States | Completed |
| Local Institution - 0075 | Orlando, Florida, United States | Completed |
| Local Institution - 0016 | Atlanta, Georgia, United States | Completed |
| Local Institution - 0101 | Park Ridge, Illinois, United States | Not Yet Recruiting |
+ 78 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05076175